ZYUS Life Sciences Corporation ZYUS

ZYUS Life Sciences Corporation (the "ZYUS" or "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel drug product candidates for chronic pain, today provided a general business update and announced changes in executive leadership, effective September 14, 2026. As part of this business update, trading in the Company's common shares (the "Shares") on the TSX Venture Exchange (the "TSXV") commenced at market open on September 14, 20

ZYUS Life Sciences Corporation ("ZYUS" and or the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today provides an update regarding its liquidity position, working capital, certain outstanding financial obligations and the measures being undertaken by the Company to strengthen its financial position and address its working capital deficiency, and announces its reinstatement

ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, is pleased to announce that its wholly-owned subsidiary, ZYUS Life Sciences Inc. ("ZYUS Inc."), has completed its secured loan financing (the "Secured Loan"). The Secured Loan was completed with certain lenders (the "Lenders"), including insiders of the Company, in nine tranches for aggregate